Rational symptomatic therapy for chronic pruritus

被引：8

作者：

Ständer S. ^{[1
,2
]}

机构：

[1] Abteilung für Klinische Neurodermatologie, Klinik und Poliklinik für Hautkrankheiten, Universitätsklinikum Münster

[2] Abteilung für Klinische Neurodermatologie, Klinik und Poliklinik für Hautkrankheiten, Universitätsklinikum Münster, 48149 Münster

来源：

Der Hautarzt | 2006年 / 57卷 / 5期

关键词：

Antipruritic therapy; Cannabinoids; Itch; Prurigo; Pruritus;

D O I：

10.1007/s00105-006-1123-x

中图分类号：

学科分类号：

摘要：

Chronic pruritus is a difficult-to-treat problem which accompanies many dermatologic and systemic diseases. Frequently, therapy is ineffective and prolongs the pruritus. Thus significant costs arise for the health system, which are clearly lowered by a rational therapy concept. Extensive knowledge about both topical and systemic therapy of pruritus has been acquired in recent years. Currently, new therapeutic approaches are available, which intervene in different pruritogenic mechanisms. Substances can block the cutaneous pruritus induction (e.g. antihistamines, leukotriene antagonists, cannabinoid agonists) or mediate central effects such as the inhibition of pruritus transmission via the spinal cord (e.g. naltrexone, gabapentin) or the suppression of the cerebral itch perception (e.g. antidepressants, neuroleptics). Usually combining several therapeutic principles is necessary in order to suppress chronic pruritus with lasting effect. The most effective approach is to gradually combine therapies, always considering both the medical and financial impacts. © Springer Medizin Verlag 2006.

引用

页码：403 / 410

页数：7

共 24 条

[1]

Amsellem C., Czarlewski W., Lagarde M., Pacheco Y., Inhibitory effect of loratadine on leukotriene B4 production by neutrophils either alone or during interaction with human airway epithelial cells, Pulm Pharmacol Ther, 11, pp. 245-252, (1998)

[2]

Andoh T., Kuraishi Y., Inhibitory effects of azelastine on substance P-induced itch-associated response in mice, Eur J Pharmacol, 436, pp. 235-239, (2002)

[3]

Biondi M., Arcangeli T., Petrucci R.M., Paroxetine in a case of psychogenic pruritus and neurotic excoriations, Psychother Psychosom, 69, pp. 165-166, (2000)

[4]

Brune A., Metze D., Luger T.A., Stander S., Antipruritische Therapie mit dem oralen Opiatrezeptorantagonisten Naltrexon: Offene, nicht-placebo-kontrollierte Anwendung bei 133 Patienten, Hautarzt, 55, pp. 1130-1136, (2004)

[5]

Edmonds E.V., Riaz S.N., Francis N., Bunker C.B., Nodular prurigo responding to topical tacrolimus, Br J Dermatol, 150, pp. 1216-1217, (2004)

[6]

Gralow I., Pharmakologische Therapie, Schmerztherapie Interdisziplinär, pp. 318-319, (2002)

[7]

Manenti L., Vaglio A., Gabapentin for uraemic pruritus, Nephrol Dial Transplant, 19, pp. 3137-3139, (2004)

[8]

Reimann S., Luger T., Metze D., Topische Anwendung von Capsaicin in der Dermatologie zur Therapie von Juckreiz und Schmerz, Hautarzt, 51, pp. 164-172, (2000)

[9]

Schneider G., Gieler U., Die Haut als Spiegel der Seele. Psychosomatische Dermatologie - Aktueller Forschungsstand, Z Psychosom Med Psychother, 47, pp. 307-331, (2001)

[10]

Schurmeyer-Horst F., Fischbach R., Nabavi D., Et al., Brachioradialer Pruritus: Eine seltene, lokalisierte, neuropathische Juckreizform, Hautarzt, (2006)

← 1 2 3 →